Approximately 6.9 million Americans are living with Alzheimer’s disease. Nearly two-thirds of them are women. This is not simply a function of women living longer — though longevity does play a role. Emerging research suggests that women face distinct biological vulnerabilities to Alzheimer’s pathology, including hormonal factors, inflammatory mechanisms, and genetic risk profiles that interact differently in female biology than in male biology. The science is not settled. But it is pointing in a direction that demands more investment, not less.
What Hormones Have to Do With It
The menopause transition — during which estrogen levels decline sharply — has emerged as a potentially significant window for Alzheimer’s risk. Estrogen appears to have neuroprotective functions; its loss may accelerate the accumulation of amyloid and tau, the proteins implicated in Alzheimer’s pathology. Observational data on hormone therapy and Alzheimer’s risk are complex and contested, but the underlying question — how female reproductive biology shapes cognitive aging — is one that research has barely begun to answer.
APOE4, the strongest genetic risk factor for late-onset Alzheimer’s, has a more pronounced effect on risk in women than in men. This gene-sex interaction is real and reproducible. It is also underrepresented in clinical trial design and in the way clinicians counsel patients about their risk.
The Caregiver Burden
Women are not only the majority of Alzheimer’s patients. They are also the majority of unpaid Alzheimer’s caregivers. The mental health, physical health, and economic consequences of caregiving — predominantly borne by women, predominantly unpaid, and predominantly invisible to health policy — are substantial. A comprehensive Alzheimer’s agenda for women must address caregiving infrastructure, not only drug development.
The Research Gap
Despite women’s overrepresentation in the patient population, Alzheimer’s research has historically enrolled disproportionately male subjects in preclinical studies, making it difficult to identify sex-specific disease mechanisms or to power sex-stratified analyses in clinical trials. The NIH SABV policy was designed to correct this. Weakening that policy — as appears possible under the current NIH leadership — would be a direct setback for Alzheimer’s research in women.
The two-thirds statistic is not a footnote. It is the organizing fact of Alzheimer’s epidemiology. Research funding and clinical guidelines should reflect that.
